Ultromics

EchoGo automates AI insights for heart failure and cardiac amyloidosis, integrating into clinical echocardiography workflows.

Discover EchoGo Amyloidosis, an FDA-cleared AI tool enhancing cardiac amyloidosis screening and HFpEF detection seamlessly within existing echocardiography workflows.

Ultromics publishes resources on echocardiography’s impact through real-world evidence and peer-reviewed studies.

Akhil Narang M.D. Presents real world evidence on the integration of EchoGo Heart Failure into the clinical workflow at Northwestern.

Explore Ultromics’ blog with tons of articles and information to further understand AI-enabled cardiovascular imaging solutions.

Hear from hospitals using Ultromics AI to help identify patients with HFpEF and cardiac amyloidosis in diagnostic assessments.

Jordan Strom M.D from Havard Medical School presents findings on the comparison of EchoGo Heart Failure and standard clinical practice on patient management

Ultromics’ AI technology analyzes echocardiogram images and predicts cardiac-related mortality better than human analysis.

Breakthrough study shows AI is capable of independently reading stress echocardiograms and predicting coronary artery disease, significantly increasing detection compared to traditional methods.

EchoGo is the first AI-powered tool to automate echocardiography analysis as a cloud service, to streamline doctor’s workflows and help save them time

Ultromics provides latest features, press releases, and media coverage, with registration for updates.

Ultromics develops AI tools for medical diagnosis and offers career opportunities in medical technology.

Explore EchoGo Heart Failure reimbursement, including CPT code 0932T, Medicare payment pathways, billing guidance and reimbursement across care settings.

The aim of this investigation was to evaluate the agreement between metrics of left ventricular function produced by EchoGo Core and the equivalent metrics produced by cardiac physiologists using a competitor device.

Ultromics names Amir Hasan as its Chief Operating Officer, with 20 years of experience in healthcare informatics and innovation.

Ultromics names Gary Woodward as its Chief Technical Officer, overseeing technical strategy for product development.

Ultromics names Dr. Helen Routh as its Chairman, with global healthcare executive experience in research and business.

Ultromics names Jaco Jacobs as its Chief Regulatory and Compliance Officer, responsible for quality and regulatory strategy.

Ultromics leverages AI to enhance cardiovascular disease detection, enabling clinicians to identify complex conditions early from routine echocardiograms for improved patient outcomes.

EchoGo Heart Failure integrates AI into echocardiography to enhance heart failure detection and support reimbursement pathways.

Ultromics partners with health systems to deliver AI-driven HFpEF identification and cardiac amyloidosis screening via echocardiography.

Want to find out more about how we can help improve disease diagnosis? Contact one of our expert team members at Ultromics and we will get in touch.

Ultromics’ FDA-cleared AI identifies HFpEF and cardiac amyloidosis from echocardiography.

Ultromics | Privacy Notice